使用依达赛珠单抗逆转达比加群以促进急性卒中溶栓后的不良临床结局。 - Suppr

Suppr

超能文献

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.

作者信息

Ng Felix C, Bice James, Rodda Anne, Lee-Archer Matthew, Crompton Douglas E

机构信息

Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia.

出版信息

J Neurol. 2017 Mar;264(3):591-594. doi: 10.1007/s00415-017-8410-6. Epub 2017 Feb 6.

DOI:10.1007/s00415-017-8410-6

PMID:28168523

Abstract

摘要

相似文献

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.使用依达赛珠单抗逆转达比加群以促进急性卒中溶栓后的不良临床结局。

J Neurol. 2017 Mar;264(3):591-594. doi: 10.1007/s00415-017-8410-6. Epub 2017 Feb 6.

Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation.依达赛珠单抗辅助静脉溶栓治疗急性卒中伴达比加群：两例发生出血性转化的病例

J Neurol Sci. 2018 May 15;388:155-157. doi: 10.1016/j.jns.2018.03.021. Epub 2018 Mar 14.

Acute stroke thrombolysis following dabigatran reversal using idarucizumab.使用艾达司珠单抗逆转达比加群后进行急性卒中溶栓治疗。

Neurol India. 2019 Mar-Apr;67(2):568-570. doi: 10.4103/0028-3886.258032.

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.使用依达赛珠单抗逆转达比加群抗凝后成功进行缺血性卒中的静脉溶栓治疗：一例报告

J Med Case Rep. 2017 Aug 15;11(1):224. doi: 10.1186/s13256-017-1404-2.

Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.达比加群用依达赛珠单抗逆转后在严重心源性栓塞性卒中中的溶栓治疗：病例报告及文献综述

J Stroke Cerebrovasc Dis. 2018 Jul;27(7):e128-e131. doi: 10.1016/j.jstrokecerebrovasdis.2018.02.025. Epub 2018 Mar 16.

Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.使用依达赛珠单抗急性逆转达比加群以进行静脉溶栓作为急性卒中治疗

J Clin Neurosci. 2019 Jan;59:355-357. doi: 10.1016/j.jocn.2018.09.027. Epub 2018 Oct 9.

Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.使用依达赛珠单抗逆转达比加群酯后急性缺血性卒中的全身溶栓治疗——病例报告

J Stroke Cerebrovasc Dis. 2017 Jul;26(7):e123-e125. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.039. Epub 2017 May 4.

Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab.达比加群酯用艾达司珠单抗逆转后急性缺血性卒中成功溶栓治疗。

BMJ Case Rep. 2019 May 5;12(5):e229128. doi: 10.1136/bcr-2018-229128.

Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.达比加群抗凝治疗期间发生急性卒中，采用艾达赛珠单抗和静脉注射组织型纤溶酶原激活剂治疗。

J Stroke Cerebrovasc Dis. 2017 Jun;26(6):e102-e104. doi: 10.1016/j.jstrokecerebrovasdis.2016.12.037. Epub 2017 Apr 14.

Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?急性卒中患者应用艾达司珠单抗后静脉溶栓——血栓对溶栓的敏感性是否可能增加？

J Stroke Cerebrovasc Dis. 2019 Mar;28(3):768-773. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.019. Epub 2018 Dec 6.

引用本文的文献

Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke.达比加群酯抗凝逆转剂依达鲁单抗用于缺血性和出血性脑卒中的标准操作流程。

J Thromb Thrombolysis. 2023 Apr;55(3):506-518. doi: 10.1007/s11239-023-02772-3. Epub 2023 Feb 4.

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.依达赛珠单抗逆转达比加群后的静脉溶栓治疗：文献系统评价

Front Neurol. 2021 Jun 3;12:666086. doi: 10.3389/fneur.2021.666086. eCollection 2021.

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.使用idarucizumab逆转达比加群后，重组组织型纤溶酶原激活剂成功治疗缺血性中风：一例报告。

J Med Case Rep. 2019 Dec 26;13(1):390. doi: 10.1186/s13256-019-2326-y.

Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab.达比加群酯用艾达司珠单抗逆转后急性缺血性卒中成功溶栓治疗。

BMJ Case Rep. 2019 May 5;12(5):e229128. doi: 10.1136/bcr-2018-229128.

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke.在急性卒中患者实验室检查和影像学检查结果出来之前，艾达司珠单抗可立即逆转达比加群的抗凝作用

Front Neurol. 2019 Mar 15;10:230. doi: 10.3389/fneur.2019.00230. eCollection 2019.

Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations.日本抗凝患者卒中溶栓共识指南：对其他人群的应用

J Stroke. 2018 Sep;20(3):321-331. doi: 10.5853/jos.2018.01788. Epub 2018 Sep 30.

Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.艾达赛珠单抗（Praxbind）逆转直接凝血酶抑制剂达比加群作用的证据：RE-VERSE AD全队列分析后的综述

P T. 2017 Nov;42(11):692-698.

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.达比加群酯治疗的急性缺血性脑卒中患者应用依达鲁单抗溶栓：现有证据的系统评价。

CNS Drugs. 2017 Sep;31(9):747-757. doi: 10.1007/s40263-017-0460-x.

J Med Case Rep. 2017 Aug 15;11(1):224. doi: 10.1186/s13256-017-1404-2.

本文引用的文献

Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.依达赛珠单抗没有促凝血作用：健康志愿者中血栓形成生物标志物的评估。

Thromb Haemost. 2017 Jan 26;117(2):269-276. doi: 10.1160/TH16-05-0385. Epub 2016 Dec 1.

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.达比加群经艾达西珠单抗逆转后用于急性缺血性卒中的静脉溶栓治疗——一例报告

Ann Clin Transl Neurol. 2016 Sep 17;3(11):889-892. doi: 10.1002/acn3.346. eCollection 2016 Nov.

Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.在急性缺血性卒中全身溶栓前几分钟使用艾达司珠单抗清除达比加群。

J Neurol Sci. 2016 Nov 15;370:44. doi: 10.1016/j.jns.2016.09.010. Epub 2016 Sep 9.

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion.达比加群治疗急性缺血性卒中患者的溶栓和取栓治疗：专家意见

Int J Stroke. 2017 Jan;12(1):9-12. doi: 10.1177/1747493016669849. Epub 2016 Sep 30.

Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report.在使用依达赛珠单抗拮抗达比加群后，重组组织型纤溶酶原激活剂成功溶栓：一例报告。

J Med Case Rep. 2016 Sep 29;10(1):269. doi: 10.1186/s13256-016-1050-0.

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report.达比加群经依达赛珠单抗逆转后行静脉溶栓治疗：一例报告

Case Rep Neurol. 2016 Jun 27;8(2):140-4. doi: 10.1159/000447531. eCollection 2016 May-Aug.

Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.在使用艾达赛珠单抗拮抗后，对正在接受达比加群抗凝治疗的中风患者进行重组组织型纤溶酶原激活剂静脉溶栓治疗。

Stroke. 2016 Jul;47(7):1936-8. doi: 10.1161/STROKEAHA.116.013550. Epub 2016 Jun 14.

Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab-A Case Report.用艾达西珠单抗拮抗达比加群后对缺血性卒中进行全身溶栓治疗——病例报告

J Stroke Cerebrovasc Dis. 2016 Aug;25(8):e126-7. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.006. Epub 2016 May 25.

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.静脉注射阿替普酶用于急性缺血性脑卒中的纳入和排除标准的科学依据：美国心脏协会/美国卒中协会医疗保健专业人员的声明。

Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Epub 2015 Dec 22.

Idarucizumab for Dabigatran Reversal.达比加群酯逆转剂依达鲁珠单抗。

N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验